News Details

( 27/12/2017 11:59)
Aurobindo Pharma - Press Release

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2017, titled "Aurobindo Pharma receives USFDA Approval for Fondaparinux Sodium Injection".

ATTENTION INVESTORS "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION